Cibus, Inc. (Nasdaq: CBUS), a leading agricultural
technology company that develops and licenses plant traits to seed
companies for royalties, announced the opening of its Oberlin
facility in San Diego with its first Production Run. The 32,000
square foot Oberlin facility, powered by Cibus’ proprietary Trait
Machine™ process, is the first high-throughput trait production
system for plants. The completion of this facility is an important
step in Cibus’ vision of the Future of Breeding that integrates
High Throughput Gene Editing Systems as extensions of seed company
breeding programs. With the Trait Machine process, Cibus is able to
fundamentally change the way seed companies bring new traits into
their advanced product pipelines and significantly accelerate the
pace at which new trait innovation is delivered to the farmers.
“The Cibus Trait Machine process changes how agricultural trait
products are commercialized using proprietary breeding
technologies. It allows customers to select their most appropriate
elite germplasm to be edited by Cibus. Cibus, in turn, returns to
its customers seeds which contain the edits and can be used
immediately in the advanced stage of their customer’s breeding
program,” said Peter Beetham, President and Chief Operating Officer
of Cibus. Beetham added: “This is the ‘Future of Breeding’ and why
the Trait Machine and Oberlin facility are so important. We are
enabling a new scale and speed for farmers to access new traits
that will help them produce higher yields at lower costs, in a more
sustainable way to address the challenges of climate change.”
The Trait Machine process employed at the Oberlin facility
integrates crop specific RTDS® cell biology
platforms with a series of gene editing technologies to enable a
system of end-to-end crop specific precision breeding. Oberlin is
currently operational for canola, winter oilseed rape, and rice.
The company is dedicated to also establish cell biology platforms
for soybean, wheat, and corn within the foreseeable future – the
work on soybean is most advanced. Cibus has developed traits for
both canola and winter oilseed rape, and in 2023, began
transferring back to customers their elite germplasm with Cibus
traits. The high-throughput capacity provided by the Oberlin
production facility is important to enable Cibus to meet the demand
from its seed company customers for its proprietary traits and for
the development of future traits.
“The opening and commissioning of Oberlin, provides Cibus the
needed production capacity to support the commercial launch of our
developed traits in canola, winter oilseed rape, and rice,” said
Andrew Walker, Cibus’ Vice President Production. “We are already
initiating gene editing production runs directly in the elite
germplasm of eleven different seed companies who have provided
Cibus the materials to edit our traits directly into their elite
lines. This type of gene editing production system allows our
customers to bypass the conventional trait introgression breeding
approach which can be time consuming, labor intensive, and less
precise.”
“With Oberlin now fully operational, we are just scratching the
surface on the potential of high-throughput gene-editing. This is
the start of a new era. Our expectation is that it will be the
model for how gene-editing-as-a-service is accessed by seed
companies going forward, with the ultimate goal of providing
innovation that delivers benefits directly to the farmers.” added
Greg Gocal, Executive Vice President and Chief Scientific Officer
of Cibus. “In addition, as this facility increases the scale and
throughput of our gene-editing processes, it also allows us to more
rapidly test and prototype new trait concepts, building on the
success of our advanced commercial-ready traits.”
About the Trait Machine™A key element of Cibus’
technology breakthrough is its Trait Machine process. The Trait
Machine process is a crop specific application of Cibus’ patented
Rapid Trait Development System (RTDS). The
proprietary technologies in RTDS integrate
crop specific cell biology platforms with a series of gene editing
technologies to enable a system of end-to-end crop specific
precision breeding. It is the core technology platform for Cibus’
Trait Machine™: the first standardized end-to-end semi-automated
crop specific gene editing system that directly edits a seed
company’s elite germplasm. Each Trait Machine process requires a
crop specific cell biology platform that enables Cibus to edit a
single cell from a customers’ elite germplasm and grow that edited
cell into a plant with the Cibus edits. Cibus has Trait Machine
processes developed for canola, winter oilseed rape, and rice and
has already begun transferring back to customers their elite
germplasm with Cibus edits in both canola and rice.
The traits from the Trait Machine process are indistinguishable
from traits developed using conventional breeding or from nature.
Under the European Commission proposal, products from Cibus’
RTDS gene editing platform such as its pod shatter
reduction trait and Sclerotinia resistant traits for canola and
winter oilseed rape would be considered ‘Conventional-like'.
Cibus believes that RTDS and the Trait Machine
process represent the technological breakthrough in plant breeding
that is the ultimate promise of plant gene editing: “High
Throughput Gene Editing Systems operating as an extension of seed
company breeding programs.” The technological moment that
materially changes the speed, breadth, and scale of trait
development.
About CibusCibus is part of the
multi-billion-dollar plant seed industry. Cibus is the leader in
the new era of high throughput gene editing technology that
can develop plant traits precisely and predictably at a
fraction of the time and cost of conventional breeding. Cibus is
not a seed company. It is a technology company that develops and
licenses traits to seed companies in exchange for royalties on seed
sales. Cibus’ target market is Productivity Traits that improve
yields, lower input costs such as chemicals, and increases the
sustainability and profitability of farming. It has a pipeline of
six productivity traits including important traits for pod shatter
reduction, disease resistance, and nutrient use efficiency. Cibus’
focus is scale, multi-crop traits that can impact greater than 100
MM acres.
Forward Looking StatementsThis press release
contains “forward-looking statements” within the meaning of
applicable securities laws, including The Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of present or historical fact included herein, including
statements regarding the benefits of the merger, Cibus’ operational
and financial performance, and Cibus’ strategy, future operations,
prospects and plans, are forward-looking statements.
Forward-looking statements may be identified by words such as
“anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,”
“could,” “would” and “will,” or the negative of these and similar
expressions.
These forward-looking statements are based on the current
expectations and assumptions of Cibus’ management about future
events, which are based on currently available information. These
forward-looking statements are subject to numerous risks and
uncertainties, many of which are difficult to predict and beyond
the control of Cibus.
There are many factors that could cause Cibus’ actual results,
level of activity, performance or achievements to differ materially
from those expressed or implied by forward-looking statements,
including factors related to: (i) risks associated with the
possible failure to realize certain anticipated benefits of the
transactions contemplated by the merger (the “Transactions”),
including with respect to future financial and operating results;
(ii) the effect of the completion of the Transactions on Cibus’
business relationships, operating results and business generally;
(iii) the outcome of any litigation related to the merger agreement
or Transactions; (iv) competitive responses to the Transactions and
changes in expected or existing competition; (v) challenges to
Cibus’ intellectual property protection and unexpected costs
associated with defending Cibus’ intellectual property rights; (vi)
increased or unanticipated time and resources required for Cibus’
platform or trait product development efforts; (vii) Cibus’
reliance on third parties in connection with its development
activities; (viii) Cibus’ ability to effectively license its
productivity traits and sustainable ingredient products; (ix) the
recognition of value in Cibus’ products by farmers, and the ability
of farmers and processors to work effectively with crops containing
Cibus’ traits; (x) Cibus’ ability to produce high-quality plants
and seeds cost effectively on a large scale; (xi) Cibus’ need for
additional funding to finance its activities and challenges in
obtaining additional capital on acceptable terms, or at all; (xii)
Cibus’ dependence on distributions from Cibus Global to pay taxes
and cover Cibus’ corporate and overhead expenses; (xiii) regulatory
developments that disfavor or impose significant burdens on
gene-editing processes or products; (xiv) Cibus’ ability to achieve
commercial success; (xv) commodity prices and other market risks
facing the agricultural sector; and (xvi) technological
developments that could render Cibus’ technologies obsolete .
In addition to these factors, other known and unknown risks and
uncertainties may adversely affect such forward-looking statements
and cause Cibus’ actual results, performance or achievements to be
materially different from those expressed or implied by the
forward-looking statements. Should one or more of these risks or
uncertainties occur, or should underlying assumptions prove
incorrect, actual results and plans could differ materially from
those expressed in any forward-looking statements. In addition, the
forward-looking statements included in this press release represent
Cibus’ views as of the date hereof. Cibus specifically disclaims
any obligation to update such forward-looking statements in the
future, except as required under applicable law. These
forward-looking statements should not be relied upon as
representing Cibus’ views as of any date subsequent to the date
hereof.
CIBUS CONTACTS:
INVESTOR RELATIONSKaren
Troeberktroeber@cibus.com 858-450-2636
MEDIA RELATIONSTed Lowentlowen@cibus.com914-343-6794
Colin Sanfordcolin@bioscribe.com203-918-4347
Cibus (NASDAQ:CBUS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cibus (NASDAQ:CBUS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024